← Bristol-Myers Squibb overview

Bristol-Myers Squibb vs AbbVie: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bristol-Myers Squibb Company (BMY)

Q3 2026
▲3▼1

Bristol-Myers Q3: Pipeline Wins, Financial Beat, But Competitive and Legal Risks Loom

  • Strong Q2 results and raised guidance Bristol reported Q2 revenue of about $13 billion and a 40% jump in earnings per share, prompting management to raise full-year revenue guidance to $49–50 billion. Analysts also increased their 2026 EPS estimates to $6.91.

    This shows the company's core financial performance and improved outlook, a key positive driver for the stock.

  • Pipeline and regulatory progress The FDA accepted mezigdomide for review, approved ZENBEXUS for multiple myeloma, and expanded Camzyos to treat pediatric patients. These advances strengthen Bristol's product lineup and help offset future patent losses.

    New drug approvals and expanded uses are direct growth catalysts that can drive future sales and investor confidence.

  • AI and infrastructure investments Bristol partnered with NVIDIA, Schrödinger, and Chai Discovery on AI-driven drug discovery, and opened a new San Diego hub and Houston plant. These investments aim to speed up research and expand manufacturing capacity.

    Long-term growth initiatives that could improve efficiency and innovation, supporting the stock's future potential.

  • Competitive and legal pressures Cytokinetics' Myqorzo threatens Camzyos, J&J's psoriasis pill challenges Sotyktu in China, and AstraZeneca merger talks collapsed. A $6.7B Celgene lawsuit revived, and CAR-T trials paused after Novartis deaths.

    These setbacks create uncertainty and potential revenue loss, weighing on the stock price.

September 2026
▲2▼2

BMY pipeline advances, but competition and safety concerns weigh

  • Pipeline and label expansion Zenbexus won FDA accelerated approval for relapsed multiple myeloma, Camzyos expanded to pediatric patients, and Arlo-cel met its Phase 2 endpoint, strengthening BMY's growth prospects.

    This is a key positive development that could drive future revenue and investor optimism.

  • Analyst EPS estimate raise Growth products now make up 56% of revenue, leading analysts to raise 2026 EPS estimates to $6.91 from $6.34, reflecting confidence in BMY's earnings power.

    This shows improved financial outlook and analyst confidence, which can positively impact the stock.

  • Competitive threat to Sotyktu J&J's oral psoriasis pill won Chinese approval, threatening Sotyktu in a market of over 8 million patients, potentially limiting BMY's growth in a key segment.

    This competitive pressure could hurt BMY's market share and revenue, a negative for the stock.

  • CAR-T trial pause Bristol paused CAR-T trials after Novartis deaths, raising regulatory and safety concerns that could delay development and pressure the stock.

    This introduces uncertainty and potential setbacks in a promising area, negatively impacting investor sentiment.

Latest
▲4

Bristol's Growth Portfolio Accelerates with New Drug Approvals and Strong Pipeline Data

  • Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.

    Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.

  • Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.

    A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.

  • Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.

    Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.

  • Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.

    Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

▲3▼2

Bristol's Cancer Pipeline Advances, but Competition and Safety Fears Linger

  • Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.

    This is a new drug approval that directly adds a future revenue driver for BMY.

  • J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.

    New competitive threat in a key market that could slow BMY's psoriasis drug sales.

  • Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.

    New clinical data that supports the durability and safety of a key growth drug.

  • CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.

    New safety event that directly affects BMY's CAR-T development and investor risk perception.

  • Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.

    New positive clinical trial result that advances a potential new therapy for BMY.

August 2026
▲2▼2

BMY beats on earnings, raises guidance, but merger talks collapse

  • Strong Q2 earnings and raised guidance Bristol-Myers Squibb reported Q2 revenue of about $13 billion, beating estimates, with earnings per share jumping 40% to $2.04. Management raised full-year guidance twice, ending at $49–50 billion, driven by Eliquis (+19%) and newer drugs like Camzyos and Reblozyl.

    This is the main positive force behind BMY's stock in August, showing better-than-expected financial performance and improved outlook.

  • FDA approves ZENBEXUS and AI partnerships expand The FDA approved ZENBEXUS for multiple myeloma, adding a new treatment to Bristol's portfolio. The company also expanded AI partnerships with Nvidia, Schrödinger, and Chai Discovery, and announced a $2.3 billion Houston plant, supporting long-term growth.

    These new developments strengthen BMY's pipeline and manufacturing, offering future revenue potential.

  • AstraZeneca merger talks collapse Reported merger talks with AstraZeneca fell apart, removing a potential takeover premium that had lifted BMY's stock. Without a merger, Bristol faces its patent cliff alone, increasing pressure to replace lost revenue from older drugs.

    This is a major negative event that removed a catalyst and leaves BMY more vulnerable to patent expirations.

  • Revived $6.7 billion Celgene lawsuit A $6.7 billion lawsuit related to the Celgene acquisition has been revived, adding legal and financial uncertainty. This could raise BMY's risk premium and pressure the stock as investors weigh potential liabilities.

    This new legal issue introduces uncertainty and potential financial burden, negatively impacting investor sentiment.

▲3▼1

Bristol Raises Outlook, Expands AI and Manufacturing Despite Legal and Competitive Risks

  • Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.

    This is the most significant new positive catalyst, directly raising revenue and profit outlook.

  • Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.

    This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.

  • Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.

    This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.

  • Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.

    This new legal development introduces a significant potential liability, a negative factor for the stock.

▲3▼1

Bristol's Q2 Beat and New Drug Approval Offset Failed Merger

  • Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.

    This is a major positive event that directly impacts BMY's financial outlook and investor confidence.

  • AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.

    The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.

  • FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.

    This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.

  • Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.

    These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

▲2

Bristol Q2 Beat and AstraZeneca Merger Talk Lift BMY

  • Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.

    This is the core fundamental news of the period and directly supports a higher valuation for BMY.

  • Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.

    This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.

  • Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.

    It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

July 2026
▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

▲2▼2

Pipeline and AI Advances Offset Pricing and Competition Pressures

  • Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

    This is a new competitive threat that directly pressures a key BMY drug.

  • Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

    This is a new pricing agreement that directly affects BMY's revenue outlook.

  • FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

    This is a new regulatory milestone that advances a promising pipeline drug.

  • Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

    These new technology investments could enhance BMY's ability to develop new drugs faster.

Q2 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

June 2026
▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

▼3▲1

Pipeline Wins Offset Medicare and China Probe Risks

  • Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

    This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

  • Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

    It is a new regulatory threat that could hurt BMY's reputation and operations.

  • Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

    It flags a new pricing risk that could lower BMY's future revenue.

  • Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

    It shows a new competitive loss that could reduce BMY's oncology revenue.

AbbVie Inc (ABBV)

Q3 2026
▲2▼2

AbbVie Q3: Earnings Beat, Pipeline Wins, But Pricing and Trial Setbacks

  • Strong Q2 Earnings and Raised Guidance AbbVie's Q2 EPS and revenue beat estimates, and the company raised full-year revenue guidance. Skyrizi and Rinvoq now make up over 47% of revenue, offsetting Humira's decline. Neuroscience guidance also increased to about $12.7 billion.

    This shows the core business outperformed and management is optimistic about future growth.

  • Pipeline Progress and New Approvals AbbVie reported Phase 3 successes, received EU approvals, and gained FDA approval for JUVMO. These advances strengthen the company's drug portfolio and future revenue potential.

    New drug approvals and trial wins are key drivers of long-term growth and investor confidence.

  • EPCORE DLBCL-1 Trial Miss and Guidance Cut The EPCORE DLBCL-1 trial missed its endpoint, leading AbbVie to cut profit guidance. The stock dropped 4% on the news, highlighting pipeline risks.

    This was a major setback that directly hurt earnings expectations and investor sentiment.

  • Pricing Pressures and Competitive Threats Trump demanded U.S. price cuts, and J&J's oral psoriasis pill won Chinese approval. Apogee's $10.9 billion acquisition will dilute earnings until 2032, and oncology sales fell 2.8% as Imbruvica dropped 27.1%.

    These factors create headwinds for revenue and profitability, weighing on the stock.

September 2026
▲2▼2

AbbVie's Pipeline Wins Offset Apogee Dilution and Oncology Decline

  • Pipeline Momentum AbbVie reported multiple Phase 3 wins: etentamig for myeloma, Qulipta for menstrual migraine, and RINVOQ for vitiligo. EU approved Rinvoq for juvenile arthritis, and the FDA approved JUVMO for Parkinson's. Early-stage data for zumilokibart and ABBV-295 also showed promise.

    These pipeline successes signal future growth and strengthen AbbVie's competitive position.

  • Neuroscience Guidance Raised AbbVie raised its neuroscience revenue guidance to about $12.7 billion, with total revenue near $67.6 billion. This reflects confidence in its neuroscience portfolio and overall business strength.

    Higher guidance indicates management's optimism and potential for earnings growth.

  • Apogee Acquisition Dilutes Earnings The $10.9 billion Apogee acquisition will reduce earnings by $0.14 per share in 2026 and $0.46 in 2027, with profits not expected until 2032. This near-term dilution pressures the stock.

    The acquisition's dilution is a significant near-term headwind for earnings per share.

  • Oncology Sales Decline Oncology sales fell 2.8% as Imbruvica dropped 27.1% due to competition and IRA pricing. Newer drugs did not fully offset the decline, highlighting challenges in this segment.

    The decline in oncology revenue weighs on overall growth and profitability.

Latest
▲4

AbbVie's pipeline wins and new drug approvals drive growth outlook

  • FDA approves JUVMO for Parkinson's disease The FDA approved JUVMO (tavapadon), the first selective D1/D5 agonist for Parkinson's, with U.S. launch set for October 2026. This adds a differentiated neuroscience drug to AbbVie's portfolio, supporting future revenue growth and lifting investor confidence.

    A major new drug approval directly expands AbbVie's revenue base and pipeline strength.

  • Zumilokibart succeeds in Phase 2 atopic dermatitis trial AbbVie's zumilokibart met the main goal in a Phase 2 study for atopic dermatitis, and the mid-dose will move into final-stage testing. This strengthens the immunology pipeline and offers a potential new treatment for a common skin condition, supporting long-term growth.

    Positive mid-stage trial results advance a key pipeline candidate, signaling future revenue potential.

  • ABBV-295 shows promising weight loss and long half-life Phase 1 data for ABBV-295 showed up to 9.8% weight loss and an 11-12 day half-life, supporting less frequent dosing. This opens a new market for AbbVie in obesity care, a high-growth area, and could become a significant future sales driver.

    Early data support a potential best-in-class obesity drug, a major new growth opportunity.

  • RINVOQ shows sustained vitiligo repigmentation in Phase 3 Phase 3 data show RINVOQ produced continued skin repigmentation in vitiligo through 76 weeks with no new safety issues. This supports a potential new use for a key drug, expanding its label and adding a new revenue stream if approved.

    Late-stage data support a new indication for a major drug, enhancing its growth prospects.

▲3▼1

AbbVie's pipeline and label wins offset oncology and pricing headwinds

  • Qulipta hits Phase 3 goal in menstrual migraine Qulipta met the main goal and all secondary goals in a late-stage trial for menstrual migraine, a condition with no approved treatment. If approved, it opens a new market of over nine million U.S. patients, adding a fresh sales driver and supporting the stock.

    New clinical win expands a fast-growing drug into an untapped market, a clear positive for future revenue.

  • Rinvoq wins EU approval for juvenile arthritis European regulators approved Rinvoq for polyarticular juvenile idiopathic arthritis, its 11th EU use. This widens the label of a key growth drug already on track for about $10.2 billion in 2026 sales, reinforcing confidence in AbbVie's immunology growth.

    New regulatory approval directly expands a major growth drug's market and supports the bull case.

  • AI drug-discovery deals and EPKINLY approval AbbVie signed multi-year AI collaborations with Iambic and joined the AISB Bind network to speed up drug discovery, and Health Canada approved EPKINLY for relapsed follicular lymphoma. These broaden the pipeline and add a new approved use, supporting long-term growth.

    New partnerships and a new approval show pipeline expansion and fresh revenue potential.

  • Oncology sales fall on Imbruvica and IRA pricing First-half oncology sales dropped 2.8% to $3.28 billion as Imbruvica fell 27.1% on competition and Medicare drug-price changes. Newer drugs like Venclexta and Elahere grew but did not fully offset the decline, weighing on overall growth.

    A real counterweight: a key segment is shrinking due to competition and pricing pressure.

▲3▼1

AbbVie's pipeline and guidance wins offset Apogee dilution

  • Apogee acquisition dilutes near-term earnings AbbVie closed its $10.9 billion purchase of Apogee Therapeutics, adding an experimental immunology drug but cutting adjusted earnings by $0.14 per share in 2026 and $0.46 in 2027. Profit won't get a boost until 2032, so near-term investors see lower earnings and the stock faces pressure.

    This is the main new negative event this period and directly lowers reported earnings, a key driver of the stock price.

  • Etentamig succeeds in Phase 3 myeloma trial AbbVie's experimental blood-cancer drug etentamig met both main goals in a late-stage trial, with a 74% response rate versus 46% for standard care and a 60% lower risk of disease worsening. This strengthens the oncology pipeline and raises hopes for a new growth driver, supporting the stock.

    This is a major new clinical win that expands AbbVie's cancer franchise and improves long-term growth prospects.

  • Qulipta succeeds in menstrual migraine trial AbbVie's migraine drug Qulipta hit the main goal in a Phase 3 trial for menstrual migraine, reducing migraine days with a convenient dosing schedule. Qulipta sales already grew 31% to $350 million last quarter, so a new use could add revenue and lift the stock.

    This is a new positive trial result that could expand the label and sales of an already fast-growing drug.

  • Neuroscience outlook raised on broad growth AbbVie lifted its 2026 neuroscience revenue forecast to about $12.7 billion and total revenue to roughly $67.6 billion, after first-half neuroscience sales jumped 21.8%. Strong demand across Vraylar, Botox, Qulipta, Ubrelvy and Vyalev gives investors more confidence in future profits, pushing the stock up.

    This is a new guidance raise that directly improves revenue expectations and signals broad-based demand strength.

August 2026
▲3▼2

AbbVie's Skyrizi-Rinvoq Momentum Outweighs Pricing and Competition Risks

  • Skyrizi and Rinvoq Now Over 47% of Revenue AbbVie's two newer drugs, Skyrizi and Rinvoq, now make up more than 47% of total revenue and are expected to top $31 billion this year, more than offsetting declining sales of older Humira.

    This shows the core growth engine replacing Humira, a key positive force for the stock.

  • Neuroscience Guidance Raised and Pipeline Advances AbbVie raised its neuroscience revenue guidance to about $12.7 billion, and reported promising lung cancer data plus a European filing for a subcutaneous version of Skyrizi for Crohn's disease, strengthening future growth prospects.

    These pipeline and guidance updates point to new sources of revenue and expanded use of existing drugs.

  • Citadel Hedge Fund Boosts Stake 547% Citadel, a major hedge fund, increased its ownership stake in AbbVie by 547%, a sign that some large investors see strong value in the company despite recent concerns.

    A big institutional buyer can lift sentiment and signal confidence in the stock.

  • Trump Demands U.S. Price Cuts Within 60 Days President Trump demanded that AbbVie cut U.S. drug prices within 60 days, threatening its pricing power and adding regulatory uncertainty that could pressure revenue and profit margins.

    This is a new political risk that directly challenges AbbVie's ability to set prices in its largest market.

  • J&J's Oral Psoriasis Pill Wins Chinese Approval Johnson & Johnson's oral psoriasis pill Icotyde received approval in China, where 8.4 million patients could switch from injectable treatments like AbbVie's Skyrizi, posing a competitive threat in a key growth market.

    This new competition could slow Skyrizi's expansion and take market share.

▲3▼1

AbbVie's pipeline and franchise expansion offset profit-guidance cut

  • Citadel boosts AbbVie stake by 547% Ken Griffin's Citadel bought 2.68 million more ABBV shares, a 547% increase, at an average of $214.90. A major fund raising its bet signals confidence in AbbVie's long-term value and can draw other investors in, supporting the stock price.

    Large institutional buying is a fresh, concrete signal of confidence that can lift investor sentiment and demand for the shares.

  • New lung cancer data strengthens oncology pipeline AbbVie presented promising early data for several experimental lung cancer drugs at a major conference, with high response rates and manageable side effects. This broadens its pipeline beyond immunology and neuroscience, giving investors another potential growth engine and supporting the stock.

    Fresh clinical progress on multiple oncology programs adds a new growth pillar, which can improve the long-term earnings outlook.

  • Skyrizi submitted for easier Crohn's dosing in Europe AbbVie asked European regulators to approve Skyrizi as a subcutaneous (under-the-skin) induction treatment for Crohn's disease, based on positive trial data. If approved, it offers patients a more convenient option and extends Skyrizi's reach, supporting future sales and the stock.

    A regulatory filing that could widen a key drug's use is a concrete pipeline expansion, not just a repeat of past results.

  • J&J's oral psoriasis pill approved in China Johnson & Johnson won Chinese approval for Icotyde, a once-daily pill for plaque psoriasis, a market with over 8.4 million patients where AbbVie's Skyrizi competes. A convenient oral option could take share from injectables like Skyrizi, weighing on AbbVie's growth prospects in China.

    This is a new competitive threat in a large market that could pressure sales of a key AbbVie drug.

▲2▼2

AbbVie's core drugs stay strong, but pricing pressure and pipeline setback weigh

  • Trump demands drug price cuts President Trump sent letters to major drugmakers, including AbbVie, demanding U.S. prescription price cuts within 60 days. This threatens future pricing power and revenue, pushing the stock down as investors worry about lower profits.

    This is a new regulatory threat that directly pressures AbbVie's pricing and future earnings.

  • Skyrizi and Rinvoq fuel growth AbbVie's newer immunology drugs Skyrizi and Rinvoq now make up over 47% of total revenue, with combined sales expected to exceed $31 billion this year. Their rapid growth is replacing declining Humira sales and supports the stock's long-term value.

    This shows the core business is successfully transitioning beyond Humira, a key driver of future revenue.

  • Neuroscience outlook raised AbbVie raised its 2026 neuroscience revenue forecast to about $12.7 billion, driven by strong sales of Vraylar, migraine drugs Ubrelvy and Qulipta, and Botox Therapeutic. This diversification adds a growing revenue stream and boosts investor confidence.

    This is a new positive update showing another part of AbbVie's business is performing well and raising guidance.

  • Epcoritamab trial fails survival goal Genmab and AbbVie confirmed that the Phase 3 trial of epcoritamab for a type of lymphoma did not meet its main overall survival goal. This pipeline setback could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that could hurt future oncology revenue prospects.

July 2026
▲3▼1

AbbVie's Q2 Beat and EU Approvals Offset by Trial Miss and Profit Guidance Cut

  • EU Approvals Expand Drug Labels AbbVie won European approvals for TEPKINLY in follicular lymphoma, Boey for frown lines, and RINVOQ for alopecia areata, broadening its oncology, aesthetics, and immunology offerings. These label expansions can drive future revenue growth.

    New approvals are a key positive development that can boost investor confidence and future sales.

  • Q2 Earnings Beat and Guidance Raise AbbVie reported Q2 EPS of $3.65 and revenue of $16.99 billion, beating estimates. Management raised full-year revenue guidance by $300 million, citing strong growth in Skyrizi, Rinvoq, and neuroscience.

    The earnings beat and guidance raise show operational strength and support the bull case.

  • Voluntary Pricing Deals Reduce Uncertainty AbbVie entered voluntary most-favored-nation pricing agreements, which lessen regulatory uncertainty around drug pricing. This proactive step may stabilize the pricing environment and reduce political risk.

    Reduced regulatory uncertainty is a positive for the stock as it removes a potential overhang.

  • Trial Miss and Profit Guidance Cut The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint, hurting oncology sentiment. Additionally, a $291 million acquired IPR&D charge led AbbVie to cut full-year adjusted earnings guidance, sending shares down 4%.

    The trial failure and earnings guidance cut are significant negatives that pressured the stock.

▲2▼2

AbbVie beats Q2, raises revenue outlook, but full-year profit guidance cut

  • Q2 beat and raised revenue guidance AbbVie beat Q2 estimates with $3.65 EPS and $16.99B revenue, and raised full-year revenue guidance by $300M on strong Skyrizi, Rinvoq and neuroscience growth. This shows the core business is performing well, supporting the stock's long-term value.

    This is the main new positive event this period, directly driving the stock's fundamental outlook.

  • Full-year profit guidance lowered Despite the revenue beat, AbbVie cut its full-year adjusted earnings outlook, partly due to a $291M charge for acquired IPR&D and milestone expenses. This disappointed investors and caused shares to fall 4%, as it signals near-term profit pressure.

    This is the key negative event this period, explaining the immediate stock drop and investor concern.

  • EU approval of RINVOQ for alopecia areata AbbVie won European approval for RINVOQ in severe alopecia areata, expanding its immunology franchise. This adds a new revenue stream and reinforces RINVOQ's growth potential, which is positive for the stock.

    This is a new regulatory win that expands the market for a key drug, supporting future sales.

  • Epcoritamab trial setback The Phase 3 EPCORE DLBCL-1 trial for epcoritamab missed its overall survival endpoint in the U.S., a setback for AbbVie's oncology pipeline. This could delay or reduce the drug's potential, weighing on sentiment.

    This is a new negative pipeline event that affects future growth prospects.

▲3▼1

AbbVie's pipeline wins approvals but faces trial setback and new competition

  • EU approval of TEPKINLY for follicular lymphoma The European Commission approved AbbVie's TEPKINLY combination for relapsed follicular lymphoma, a chemotherapy-free option that cut progression risk by 79%. This expands AbbVie's oncology portfolio and adds a new revenue stream, supporting long-term growth.

    New approval directly boosts AbbVie's oncology franchise and future sales.

  • EU approval of Boey for frown lines Allergan Aesthetics, part of AbbVie, won EU approval for Boey, a fast-acting botulinum toxin for frown lines. This strengthens AbbVie's aesthetics business and offers a new treatment option, potentially driving revenue growth.

    New product approval expands AbbVie's aesthetics portfolio and revenue potential.

  • Voluntary drug-pricing deals with Trump administration AbbVie agreed to voluntary most-favored-nation pricing with the Trump administration. While this may lower prices for some drugs, AbbVie's newer immunology drugs Skyrizi and Rinvoq are expected to offset Humira's decline, and the deal reduces regulatory uncertainty.

    New pricing agreement affects AbbVie's revenue but is manageable given strong new drugs.

  • Epcoritamab trial misses overall survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial did not meet its primary overall survival endpoint in the U.S. This setback could delay or reduce the drug's potential in this indication, weighing on sentiment.

    New negative trial result directly impacts AbbVie's oncology pipeline and investor confidence.

Q2 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

June 2026
▲2▼2

AbbVie's $10.9B Apogee Deal and Drug Wins Lift Shares to 52-Week High

  • Apogee Acquisition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining a potential rival to Dupixent. The deal is funded from operating cash flow, so no new debt is needed.

    This major acquisition is a key new event that could drive future growth and investor sentiment.

  • Drug Label Expansions and Phase 3 Wins AbbVie expanded the labels for Skyrizi and Rinvoq and reported positive Phase 3 results. This pushed the stock to a 52-week high and added $43 billion in market value.

    These clinical and regulatory successes directly boosted the stock price and market value.

  • Congressional Probe into China Trials A bipartisan congressional probe into AbbVie's China clinical trials could raise compliance costs and delay drug pipelines. This adds uncertainty and potential headwinds for the company.

    This regulatory risk is a new negative factor that could weigh on the stock.

  • Decelerating Growth of Key Drugs Growth of key drugs Skyrizi and Rinvoq is slowing, which could pressure the stock's rich valuation. Investors may worry about future revenue growth.

    Slowing growth is a fundamental concern that could limit upside for the stock.

▲2▼2

AbbVie hits 52-week high on Apogee deal and drug approvals, but China probe and slowing drug growth weigh

  • Apogee acquisition and expanded drug labels drive record high AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, adding a promising immunology drug. It also won approvals to expand Skyrizi and Rinvoq to new patient groups. These moves strengthen future growth and pushed the stock to a 52-week high, adding $43 billion in market value in a week.

    This is the main reason the stock hit a new high and reflects the biggest new development this period.

  • US Congress opens bipartisan probe into AbbVie's China clinical trials A House committee is investigating AbbVie's clinical trials in China, including sites linked to the Chinese military and in Xinjiang. While no illegal conduct is alleged, the probe could lead to tighter oversight, higher compliance costs, and restrictions on trial locations, potentially delaying drug pipelines and hurting the stock.

    This is a new risk that could negatively affect the stock and was not in earlier reports.

  • Growth of key drugs Skyrizi and Rinvoq shows signs of slowing Skyrizi's growth decelerated to 29.2% from 31.9%, and Rinvoq's growth slowed to 20.2% from 28.6%. These drugs are critical to AbbVie's post-Humira strategy, and any sustained slowdown could pressure the stock's valuation, which already prices in high growth.

    This is a new concern about the company's growth engine that could weigh on the stock.

  • Positive late-stage trial results and new drug approvals bolster pipeline AbbVie reported positive Phase 3 data for venetoclax in leukemia and epcoritamab in lymphoma, and won approvals for MAVIRET in hepatitis C, SKYRIZI in pediatric psoriasis, and a new neurotoxin Boey. These advances strengthen the company's oncology and aesthetics portfolios, supporting long-term revenue growth.

    These are new clinical and regulatory wins that reinforce AbbVie's pipeline and future sales potential.

▲3

AbbVie's $10.9B Apogee buy expands immunology pipeline

  • Apogee acquisition adds promising immunology drug AbbVie agreed to buy Apogee Therapeutics for $10.9 billion in cash, gaining zumilokibart, a potential rival to Dupixent for eczema and asthma. The deal strengthens AbbVie's immunology franchise and pipeline, which investors view as a positive for long-term growth.

    This is the main new event driving ABBV's stock and future prospects.

  • Deal funded without debt, preserving financial flexibility AbbVie will pay for Apogee entirely from operating cash flow, avoiding new debt. This keeps its balance sheet strong and reduces financial risk, which supports the stock price.

    Shows the acquisition is financially manageable and not a strain.

  • Near-term earnings dilution, but long-term growth The deal won't add to adjusted earnings per share until 2032, so it may slightly weigh on near-term profits. However, it positions AbbVie for future growth in immunology, balancing the short-term cost with long-term benefit.

    Highlights the trade-off investors are weighing.

  • Analysts see reasonable premium and strategic fit Citi and other analysts said the 49% premium is not excessive given Apogee's strong data and scarce immunology assets. The deal also fits with AbbVie's existing commercial infrastructure, supporting a positive view.

    Analyst validation reinforces the market's positive reaction.

© 2026 MarketIVWhy